Related Experiment Video
Updated: Jul 19, 2026

Myeloid Cell Isolation from Mouse Skin and Draining Lymph Node Following Intradermal Immunization with Live Attenuated Plasmodium Sporozoites
Published on: May 18, 2016
AAV vectors encoding malarial antigens stimulate antigen-specific immunity but do not protect from parasite infection
Grant J Logan1, Lina Wang, Maolin Zheng
1Gene Therapy Research Unit, Children's Medical Research Institute and The Children's Hospital at Westmead, Westmead, Australia.
Abstract:
This study explores the utility of recombinant adeno-associated virus (rAAV) as a genetic vaccine delivery system using muscle as a target tissue. A single injection of rAAV encoding the malarial antigens MSP4 (Plasmodium falciparum) or MSP4/5 (Plasmodium yoelii) stimulated long-term antigen-specific antibody responses. Anti-MSP4/5 immunity stimulated by AAV was not protective against P. yoelii infection and efforts taken to augment antibody responses against MSP4/5, either by priming with plasmid DNA or AAV and boosting with rAAV were unsuccessful. Alternative strategies such as inclusion of genetic adjuvants into the AAV vector will be necessary to stimulate an adequate level of anti-malarial protective immunity in this model.
Insights
Recombinant adeno-associated virus (rAAV) shows potential for genetic vaccines targeting malaria antigens. However, current rAAV delivery alone does not induce protective immunity against Plasmodium yoelii infection.
Area of Science:
- Immunology
- Virology
- Vaccinology
Background:
- Recombinant adeno-associated virus (rAAV) is being investigated as a novel genetic vaccine delivery system.
- Muscle tissue is a potential target for in vivo genetic vaccination.
Purpose of the Study:
- To evaluate the efficacy of rAAV as a genetic vaccine delivery system for malaria antigens.
- To assess the induction of antigen-specific antibody responses and protective immunity.
Main Methods:
- Single intramuscular injection of rAAV vectors encoding Plasmodium falciparum MSP4 or Plasmodium yoelii MSP4/5 antigens.
- Assessment of long-term antibody responses and challenge with P. yoelii infection.
- Evaluation of alternative strategies including DNA priming and AAV boosting.
Main Results:
- rAAV delivery successfully induced long-term antigen-specific antibody responses against MSP4 and MSP4/5.
- Immunity generated by AAV against MSP4/5 did not confer protection against P. yoelii challenge.
- Priming with DNA or AAV, followed by rAAV boosting, failed to enhance protective antibody responses.
Conclusions:
- While rAAV can elicit antibody responses, it is insufficient for protective anti-malarial immunity in this model.
- Further strategies, such as incorporating genetic adjuvants into rAAV vectors, are required to achieve adequate protective immunity.
Related Concept Videos
Malaria
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Symbiosis

